Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM, Nakamura Y, Cox NJ, Stephens PJ, Miller VA, Ross JS, Chen D, Safgren SL, Kuffel MJ, Ames MM, Kalari KR, Gomez HL, Gonzalez-Angulo AM, Burgues O, Brauch HB, Ingle JN, Ratain MJ, Yelensky R
J Natl Cancer Inst. 2014 107 (2)

PMID: 25490892 · PMCID: PMC4565524 · DOI:10.1093/jnci/dju401

MeSH Terms (21)

Adult Aged Antineoplastic Agents, Hormonal Biomarkers, Tumor Breast Neoplasms Cytochrome P-450 CYP2D6 Disease-Free Survival DNA, Neoplasm Female Formaldehyde Genotype Humans Loss of Heterozygosity Middle Aged Mouth Mucosa Paraffin Embedding Receptor, ErbB-2 Receptors, Estrogen Survival Analysis Tamoxifen Tissue Fixation

Connections (1)

This publication is referenced by other Labnodes entities: